Smoking-thrombolysis paradox: Recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke

Stroke

Volumn 44, Issue 2, 2013, Pages 407-413

  Kufner, Anna ^a   Nolte, Christian H ^a,b   Galinovic, Ivana ^b   Brunecker, Peter ^b   Kufner, Gerald M ^c   Endres, Matthias ^b   Fiebach, Jochen B ^a,b   Ebinger, Martin ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Center for Stroke Research Berlin   (Germany)

^c Kingston Neurological Associates   (United States)

Author keywords

ischemic stroke; MRI; reperfusion; smoking; thrombolysis

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; BRAIN ISCHEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING UNIT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPERFUSION; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; REPERFUSION; RETROSPECTIVE STUDIES; SMOKING; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84872937481     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.662148     Document Type: Article

References (36)

1. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976;2:1525-1536.
2. Grines CL, Topol EJ, O'Neill WW, George BS, Kereiakes D, Phillips HR, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation. 1995;91:298-303.
3. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, et al. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005;45:321-323.
4. Purcell IF, Newall N, Farrer M. Lower cardiac mortality in smokers following thrombolysis for acute myocardial infarction may be related to more effective fibrinolysis. QJM. 1999;92:327-333.
5. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation. 1993;87:53-58.
6. Aune E, Røislien J, Mathisen M, Thelle DS, Otterstad JE. The "smoker's paradox" in patients with acute coronary syndrome: a systematic review. BMC Med. 2011;9:97.
7. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, et al. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002;13:133-139.
8. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
9. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973-977.
10. Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol. 2010;30:75-79.
11. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936-1941.
12. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet. 1987;2:986-988.
13. Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. Neurology. 2005;65:293-295.
14. Hotter B, Pittl S, Ebinger M, Oepen G, Jegzentis K, Kudo K, et al. Prospective study on the mismatch concept in acute stroke patients within the first 24 h after symptom onset - 1000Plus study. BMC Neurol. 2009;9:60.
15. Bogousslavsky J, Kaste M, Skyhoj Olsen T, Hacke W, Orgogozo JM. Risk factors and stroke prevention. European Stroke Initiative (EUSI). Cerebrovasc Dis. 2000;10 Suppl 3:12-21.
16. Joseph LN, Babikian VL, Allen NC, Winter MR. Risk factor modification in stroke prevention: the experience of a stroke clinic. Stroke. 1999;30:16-20.
17. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. Aha guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases - American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial - TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
19. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings: TIMI study group. N Engl J Med. 1985;312:932-936
20. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al.; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7: 299-309.
21. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al.; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
22. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al.; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
23. Forey B, Hamling J, Hamling J, Lee PN. Germany: Web edition. International smoking statistics: a collection of historical data from 30 economically developed countries. Wolfson Institute of Preventive Medicine; 2008. http://www.pnlee.co.uk/ISS.htm. Accessed 21 June 2012.
24. Rossnagel K, Jungehülsing GJ, Nolte CH, Müller-Nordhorn J, Roll S, Wegscheider K, et al. Out-of-hospital delays in patients with acute stroke. Ann Emerg Med. 2004;44:476-483.
25. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J. 2008;156:1163-1169.
26. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53:126-131.
27. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights: Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:1222-1229.
28. Gomez MA, Karagounis LA, Allen A, Anderson JL. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction: TEAM-2 Investigators-Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. Am J Cardiol. 1993;72:373-378.
29. Parsons MW, Christensen S, McElduff P, Levi CR, Butcher KS, De Silva DA, et al.; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab. 2010;30:1214-1225.
30. Zangerle A, Kiechl S, Spiegel M, Furtner M, Knoflach M, Werner P, et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology. 2007;68:39-44.
31. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, et al.; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke- MOnitoring STudy (SITS-MOST). Stroke. 2008;39:3316-3322.
32. Soares BP, Tong E, Hom J, Cheng SC, Bredno J, Boussel L, et al. Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. Stroke. 2010;41:e34-e40.
33. Cho KH, Kim JS, Kwon SU, Cho AH, Kang DW. Significance of susceptibility vessel sign on T2 -weighted gradient echo imaging for identification of stroke subtypes. Stroke. 2005;36:2379-2383.
34. De Silva DA, Churilov L, Olivot JM, Christensen S, Lansberg MG, Mlynash M, et al.; EPITHET-DEFUSE Investigators. Greater effect of stroke thrombolysis in the presence of arterial obstruction. Ann Neurol. 2011;70:601-605.
35. Ernst E, Matrai A, Schmölzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol. 1987;65: 485-487.
36. Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci (Lond). 2001;100:459-465.